Two well-received precision oncology IPOs closed out the week, joined by a successful ophthalmic specialty IPO and an immunotherapy debut that fell flat. P53 mutation hunter PMV Pharmaceuticals Inc. charged out the gate, raising $211.8 million, while Prelude Therapeutics Inc. took in $158.2 million. Read More
DUBLIN – Galecto Biotech Inc. raised $64 million in a series D funding round, which will enable the company to complete a phase IIb trial of its lead drug candidate, the inhaled galectin-3 inhibitor GB-0139, in idiopathic pulmonary fibrosis, and to move two other programs into phase II studies, in liver fibrosis and myelofibrosis, before year-end. Read More
PERTH, Australia – Sydney-based Recce Pharmaceuticals Ltd. completed a placement of AU$27.95 million (US$19.69 million) to advance its synthetic anti-infective pipeline to address antibiotic-resistant superbugs and emerging viral pathogens. Read More
The always-busy American Society of Hematology meeting in December promises to include some especially intriguing datasets from the bispecific antibody space, as multiple players are likely to unveil findings related to their CD20xCD3 prospects. Read More
Researchers at the University of Virginia have used a retrospective database analysis to show that the use of nucleoside reverse transcriptase inhibitors for the treatment of HIV or hepatitis B reduced the risk of developing type 2 diabetes by 33%. Read More
Without the COVID-19 pandemic, projected values of biopharma nonprofit collaborations and grants would be 72% and 30% below last year’s levels, although it is impossible to know what deals may have come to fruition in a world absent of the disruptive SARS-CoV-2 virus. Read More
HONG KONG – Novartis AG was cited during the recent 2020 KoNECT-MOHW-MFDS International Conference as an example of a biopharma firm staying ahead of the artificial intelligence curve. During this week’s 2020 Bioplus Interphex Korea conference, Won Kim, head of innovation at Novartis Korea, described some of the firm’s latest forays into AI, including negotiations with potential partners to develop an AI image analysis solution for retinal diseases. Read More
New hires and promotions in the biopharma industry, including: Accent, Clover, Collegium, Graybug Vision, Ipsen, Medexus, Psychogenics, Respirerx, Surrozen. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Apeiron, Beyondspring, BMS, Genfit, Hansa, Marinus, Menarini, Novavax, Radius Rhizen, Uniqure. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abcellera, Amarna, Clover, Dynavax, Endo, Fulcrum, Grand River Aseptic, GSK, IGM, Immunoprecise, J&J, Janone, Lambdavision, Litevax, Molecular Partners, Novavax, Par, Rockwell, Valo. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Adial, Alexion, Blueprint, Brickell, Cardiol, Daiichi, Eisai, Galapagos, Gilead, Kaken, Neurophth, Olix, Oncoheroes, Rakuten, Remegen, Spirovant, Vertex, Xiangxue. Read More
